Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

(EBC) patients receiving Kisqali in 1-year post-treatment analysis1Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients1Rising br ...

Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali(R) (ribociclib) plus endocrine therapy (ET, a non-steroidal ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...

With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

Steven H. Stein currently works at Repare Therapeutics, Inc., as Director from 2024, Incyte Corp., as Chief Medical Officer & Executive Vice President from 2016, the University of Pennsylvania, as ...

Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., (GLOBE ...

“BioNTech’s robust financial position empowers us to pursue our strategic goal of evolving into a leading biotech company with multiple oncology products by 2030.” Cost of sales was 83.8 ...

A total of 109 patients were enrolled between March 2019 and February 2023. In the interim analysis, the Data and Safety Monitoring Committee recommended early study termination. The median PFS was ...

Novartis' strategy to focus largely in areas of unmet medical need should strengthen the firm's pricing power. The firm's key areas of innovation focus on oncology, immunology, neurology ...